Articles

1. Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group

   • Mercedes Salgado Fernández
   • Margarita Reboredo López
   • the Galician Group of Research in Digestive Tumors (GITuD)

   Original Research Article 23 May 2024

   

2. Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patients: A Systematic Review and Meta-Analysis

   • Tai Van Nguyen
   • Diaddin Hamdan
   • Guilhem Bousquet

   Systematic Review 18 May 2024

   

3. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

   • Danielle Brazel
   • Misako Nagasaka

   Leading Article Open access 13 May 2024 Pages: 297 - 301

   

4. Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma

   • Sheridan M. Hoy

   Adis Drug Evaluation 09 May 2024 Pages: 473 - 480

   

5. Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)

   • Ondřej Fiala
   • Sebastiano Buti
   • Matteo Santoni

   Original Research Article Open access 05 May 2024

   

6. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System

   • Sara Cecco
   • Stefano Puligheddu
   • Emanuel Raschi

   Original Research Article Open access 02 May 2024 Pages: 435 - 445

   

7. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

   • Margherita Rimini
   • Gianluca Masi
   • Andrea Casadei-Gardini

   Original Research Article 01 May 2024 Pages: 359 - 370

   

8. Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study

   • Yoshinori Kagawa
   • Chaochen Wang
   • Yu Sunakawa

   Original Research Article Open access 01 May 2024

   

9. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

   • Mara Persano
   • Margherita Rimini
   • Andrea Casadei-Gardini

   Original Research Article Open access 30 April 2024

   

10. Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer

    • Yuan Li
    • Weili Zhang
    • Zhenhai Lu

    Original Research Article 30 April 2024

    

11. ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study

    • Michael Maris
    • Gilles Salles
    • Vincent Ribrag

    Original Research Article Open access 29 April 2024 Pages: 321 - 332

    

12. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes

    • Zucheng Xie
    • Yan Qin
    • Yuankai Shi

    Original Research Article 21 April 2024 Pages: 383 - 400

    

13. A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone

    • James R. Berenson
    • Andrea Limon
    • Robert Vescio

    Original Research Article 20 April 2024 Pages: 343 - 357

    

14. The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling

    • Hiroyuki Yamamoto
    • Hiroyuki Arai
    • Yu Sunakawa

    Original Research Article 13 April 2024 Pages: 459 - 471

    

15. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)

    • Naoya Nishioka
    • Hisao Imai
    • Hiroaki Okamoto

    Original Research Article Open access 13 April 2024 Pages: 423 - 433

    

16. Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis

    • Michele Basso
    • Carlo Signorelli
    • Giampaolo Tortora

    Original Research Article Open access 13 April 2024 Pages: 371 - 382

    

17. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer

    • Jacob B. Leary
    • Thomas Enright
    • Petros Grivas

    Original Research Article 03 April 2024 Pages: 447 - 458

    

18. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors

    • Taizo Uchimoto
    • Shuya Tsuchida
    • Haruhito Azuma

    Original Research Article 28 March 2024 Pages: 401 - 410

    

19. A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor

    • Louise Evans
    • Rick Walker
    • David S. Ziegler

    Original Research Article Open access 28 March 2024 Pages: 333 - 342

    

20. Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review

    • Etienne Brain
    • Connie Chen
    • Karen A. Gelmon

    Systematic Review Open access 28 March 2024 Pages: 303 - 320

    

21. Correction to: Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma

    • Nicole L. France
    • Hannah A. Blair

    Correction Open access 20 March 2024 Pages: 481 - 481

22. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK

    • Rachael Batteson
    • Emma Hook
    • Paul K. Paik

    Original Research Article Open access 16 March 2024 Pages: 191 - 201

    

23. Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia

    • Dian Jin
    • Haoguang Chen
    • Zhen Cai

    Original Research Article Open access 11 March 2024 Pages: 237 - 249

    

24. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients

    • Keisuke Onoi
    • Tadaaki Yamada
    • Koichi Takayama

    Original Research Article 11 March 2024 Pages: 411 - 421

    

25. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review

    • Patrick Crotty
    • Karim Kari
    • Matt Vassar

    Systematic Review 11 March 2024 Pages: 161 - 173

    

26. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

    • Masahiro Tsuboi
    • Roy S. Herbst
    • Yi-Long Wu

    Summary of Research Open access 11 March 2024 Pages: 131 - 134

    

27. Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia—A Podcast

    • Elias J. Jabbour
    • Matthias Stelljes

    Commentary Open access 08 March 2024 Pages: 135 - 141

28. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer

    • Connie Kang

    Adis Drug Evaluation 06 March 2024 Pages: 289 - 296

    

29. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G

    • Toshihiko Matsumoto
    • Yoshiyuki Yamamoto
    • Kei Muro

    Original Research Article Open access 01 March 2024 Pages: 181 - 190

    

30. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation

    • Ruiying Zhao
    • Jiaqi Li
    • Yuchen Han

    Original Research Article 28 February 2024 Pages: 277 - 288

    

31. Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study

    • Gwan Hee Han
    • Hae-Rim Kim
    • Hanbyoul Cho

    Original Research Article 28 February 2024 Pages: 251 - 262

    

32. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data

    • Alexander Olkus
    • Aurelie Tomczak
    • Michael T. Dill

    Original Research Article Open access 28 February 2024 Pages: 213 - 221

    

33. DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma

    • Julia Maria Ressler
    • Erwin Tomasich
    • Anna Sophie Berghoff

    Original Research Article Open access 24 February 2024 Pages: 263 - 275

    

34. Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review

    • Urszula Żebrowska
    • Walentyna Balwierz
    • Aleksandra Wieczorek

    Systematic Review Open access 24 February 2024 Pages: 143 - 159

    

35. Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

    • Margherita Rimini
    • Eleonora Loi
    • Andrea Casadei-Gardini

    Original Research Article 12 February 2024 Pages: 223 - 235

    

36. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy

    • Tomas Buchler
    • Alexandr Poprach

    Review Article Open access 03 February 2024 Pages: 175 - 180

37. Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies

    • Bi-Cheng Wang
    • Bo-Hua Kuang
    • Guo-He Lin

    Original Research Article 30 January 2024 Pages: 203 - 212

    

38. Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)

    • Hung-Ming Wang
    • Pei-Jen Lou
    • Meng-Che Hsieh

    Original Research Article Open access 29 January 2024 Pages: 51 - 58

    

39. Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China

    • Qichen Dai
    • Kexin Feng
    • Yipeng Wang

    Original Research Article 24 January 2024 Pages: 81 - 93

    

40. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

    • Silvia Camera
    • Margherita Rimini
    • Andrea Casadei-Gardini

    Original Research Article 22 January 2024 Pages: 29 - 39

    

41. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma

    • Nicole L. France
    • Hannah A. Blair

    Adis Drug Evaluation Open access 18 January 2024 Pages: 115 - 123

    

42. Pemigatinib: A Review in Advanced Cholangiocarcinoma

    • James E. Frampton

    Adis Drug Evaluation 11 January 2024 Pages: 107 - 114

    

43. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer

    • Yu Sunakawa
    • Yasutoshi Kuboki
    • Takayuki Yoshino

    Original Research Article Open access 09 January 2024 Pages: 59 - 69

    

44. Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8⁺ Lymphocyte Repopulation in Hepatocellular Carcinoma

    • Eloïne Bestion
    • Madani Rachid
    • Philippe Halfon

    Original Research Article 22 December 2023 Pages: 95 - 106

    

45. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea

    • Yeokyeong Shin
    • Bo Hyun Moon
    • Changhoon Yoo

    Original Research Article 18 December 2023 Pages: 41 - 49

    

46. Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis

    • Brigida Anna Maiorano
    • Ugo De Giorgi
    • the MeetURO group

    Correction Open access 09 December 2023 Pages: 127 - 127

47. Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

    • Xiuning Le
    • Eric Nadler
    • John Victor Heymach

    Correction Open access 09 December 2023 Pages: 125 - 125

48. Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors

    • Serafina Martella
    • Marco Maria Aiello
    • Michele Porcu

    Review Article 08 December 2023 Pages: 13 - 28

    

49. A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis

    • Ming-Yu Lien
    • Tzer-Zen Hwang
    • Meng-Che Hsieh

    Original Research Article 02 December 2023 Pages: 71 - 79

    

50. Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer

    • Simon Fung
    • Yahiya Y. Syed

    Correction Open access 29 November 2023 Pages: 129 - 129